skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Vorsetuzumab-mafodotin (Code C88315)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Vorsetuzumab-mafodotin

Definition: An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to the auristatin analogue monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. The anti-CD70 antibody moiety of vorsetuzumab-mafodotin selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells.

Display Name: Vorsetuzumab-mafodotin

Label: Vorsetuzumab-mafodotin

NCI Thesaurus Code: C88315 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL413570  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD70 MoAb SGN70-MMAF Conjugate

External Source Codes: 
CAS Registry Number 1165741-01-4 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 660730
PDQ Open Trial Search ID 660730 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C88315
Contributing_Source CTRP
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom